RACHEL TEDESCO, NP
Nurse Practitioner · WHITEVILLE, NC
Individual Active NPI 1063056687
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 567 | 209,580 | $21,334,588 | $5,838,529 | $4,646,806 |
| 2023 | 980 | 413,794 | $36,384,509 | $11,081,077 | $8,794,866 |
| 2022 | 755 | 211,935 | $18,835,111 | $6,341,419 | $5,051,378 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | 26,128 | $12 | $9 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 17,700 | $22 | $17 |
| J0897 | Injection, denosumab, 1 mg | 10,260 | $26 | $21 |
| J2350 | Injection, ocrelizumab, 1 mg | 9,300 | $59 | $47 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 8,820 | $11 | $9 |
| J3245 | Injection, tildrakizumab, 1 mg | 7,600 | $134 | $107 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 7,560 | $18 | $14 |
| J2357 | Injection, omalizumab, 5 mg | 6,975 | $37 | $30 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 4,930 | $45 | $36 |
| J2182 | Injection, mepolizumab, 1 mg | 4,400 | $30 | $24 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3,960 | $31 | $25 |
| J0517 | Injection, benralizumab, 1 mg | 2,070 | $165 | $131 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Nurse Practitioner | 363L00000X | ✓ | 5012513 | NC |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Nurse Practitioner providers in North Carolina
- NPI 1265968770
- NPI 1346993284
- NPI 1902731862
- NPI 1003407966
- NPI 1841354560
- NPI 1174920300
- NPI 1023004637
- NPI 1770380990
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.